Literature DB >> 3709620

Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.

T Leemann, P Dayer, U A Meyer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3709620     DOI： 10.1007/bf00615971

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  14 in total

1.  Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.

Authors:  S V Otton; T Inaba; W Kalow
Journal:  Life Sci       Date:  1984-01-02       Impact factor: 5.037

2.  [Polymorphisms and deficient drug metabolism as triggers of toxic reactions (author's transl)].

Authors:  H J Dengler; M Eichelbaum
Journal:  Arzneimittelforschung       Date:  1977

3.  Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol.

Authors:  P Dayer; T Leemann; A Marmy; J Rosenthaler
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers.

Authors:  P Dayer; R Gasser; J Gut; T Kronbach; G M Robertz; M Eichelbaum; U A Meyer
Journal:  Biochem Biophys Res Commun       Date:  1984-11-30       Impact factor: 3.575

5.  Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.

Authors:  L Bertilsson; M Eichelbaum; B Mellström; J Säwe; H U Schulz; F Sjöqvist
Journal:  Life Sci       Date:  1980-11-03       Impact factor: 5.037

6.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

7.  The genetic control of bufuralol metabolism in man.

Authors:  P Dayer; L Balant; F Courvoisier; A Kupfer; A Kubli; A Gorgia; J Fabre
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

8.  Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers.

Authors:  M S Lennard; G T Tucker; J H Silas; S Freestone; L E Ramsay; H F Woods
Journal:  Clin Pharmacol Ther       Date:  1983-12       Impact factor: 6.875

9.  Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.

Authors:  J Gut; R Gasser; P Dayer; T Kronbach; T Catin; U A Meyer
Journal:  FEBS Lett       Date:  1984-08-06       Impact factor: 4.124

10.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321
View more
  36 in total

1.  Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol.

Authors:  T Andersson; P Lundborg; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Fetal drug metabolism and its possible clinical implications.

Authors:  B Krauer; P Dayer
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

3.  Pharmacogenetics and drug metabolism: an Irish perspective.

Authors:  P Holland; M Barry; J Feely
Journal:  Ir J Med Sci       Date:  1991-02       Impact factor: 1.568

4.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.

Authors:  M D Nielsen; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

6.  Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.

Authors:  C Funck-Brentano; H K Kroemer; H Pavlou; R L Woosley; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

7.  Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (+/-)-metoprolol.

Authors:  T D Leemann; K P Devi; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Impact of environmental and genetic factors on codeine analgesia.

Authors:  J Desmeules; M P Gascon; P Dayer; M Magistris
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.

Authors:  D Wu; S V Otton; B A Sproule; U Busto; T Inaba; W Kalow; E M Sellers
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

10.  Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.

Authors:  G Muralidharan; E M Hawes; G McKay; E D Korchinski; K K Midha
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.